poly(ADP-ribose) polymerase family member 12Genealiases: ARTD12 · MST109 · MSTP109 · ZC3H1 · ZC3HDC1
Q-omics provides the consensus-scored PARP12 profile across patient tissues and cancer cell-line models. PARP12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PARP12 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PARP12 protein abundance shows 21,610 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, HNSC, and PDAC as cancer lineages where PARP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP12 survival associations across molecular data types. PARP12 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP12 RNA expression–survival associations across cancer types. High PARP12 expression shows unfavorable associations in KIRC, UVM, UCEC, LIHC and LGG, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PARP12 RNA expression.
This table summarizes PARP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PARP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP12 shows higher tumor expression in HNSC, KIRC, BLCA, THCA, LIHC and STAD. The HNSC box plot shows higher PARP12 RNA expression in tumor versus normal tissue (log2 FC = +2.390, t-test p < 0.001).
This table shows molecular features associated with PARP12 in patient tissues and cancer cell lines. In patient samples, PARP12 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PARP12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
